Joshua Adam Barocas, MD

Adjunct Assistant Professor, Medicine

Joshua Barocas


I lead an interdisciplinary research program that is specifically aimed at the goal of improving health outcomes for patients with infectious diseases including HIV and HCV, substance use disorders, and other vulnerable populations. My research, which uses clinical epidemiology, health economics, simulation modeling, and cost-effectiveness, informs clinical-decision making and health policy to answer clinically- and policy-relevant questions. I am engaged in research using these innovative methods to help understand the impact of and improve upon policies that affect people who use drugs infected with or at high risk for infections. My research is currently been funded by NIDA in the form of both a K01 and a DP2 award as well as multiple grants for which I am a Co-Investigator. I have also received NIAID, the Providence/Boston Center for AIDS Research (CFAR), the BU-CTSI, and the MGH Executive Committee on Research Fund for Medical Discovery. I currently serve as Director of the Health Economics and Modeling Core for the Massachusetts HEALing Communities Study, an NIH-funded grant to significantly reduce overdose. I am the previous recipient of the Charles A. King Trust Research Award, and the prestigious AAMC Herbert W. Nickens Faculty Fellowship Award, which recognizes a junior faculty member who demonstrates leadership potential in addressing inequity in health care. I have published my work and editorials in leading journals such as NEJM, Lancet Public Health, JAMA Internal Medicine, AJPH, Addiction, Clinical Infectious Diseases, and Annals of Internal Medicine. My work has been widely cited in the media, including the Boston Globe, U.S. News and World Report, and NPR.


  • George Washington University School of Medicine, MD
  • Washington University in St. Louis, BA


  • Published on 6/28/2023

    Palis H, Barocas JA, Moe J, Scow M, Sedgemore KO, Slaunwhite AK, Buxton JA. Rising rates of infective endocarditis in North America: An urgent need for attention to the rapidly changing unregulated drug supply. Int J Drug Policy. 2023 Aug; 118:104110. PMID: 37390695.

    Read at: PubMed
  • Published on 5/2/2023

    Barocas JA, Nall SK, Axelrath S, Pladsen C, Boyer A, Kral AH, Meehan AA, Savinkina A, Peery D, Bien M, Agnew-Brune C, Goldshear J, Chiang J, Linas BP, Gonsalves G, Bluthenthal RN, Mosites E. Population-Level Health Effects of Involuntary Displacement of People Experiencing Unsheltered Homelessness Who Inject Drugs in US Cities. JAMA. 2023 May 02; 329(17):1478-1486. PMID: 37036716.

    Read at: PubMed
  • Published on 4/3/2023

    Jawa R, Tin Y, Nall S, Calcaterra SL, Savinkina A, Marks LR, Kimmel SD, Linas BP, Barocas JA. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Netw Open. 2023 Apr 03; 6(4):e237888. PMID: 37043198.

    Read at: PubMed
  • Published on 1/6/2023

    Jurecka CA, Barocas JA. Using Evidence to Inform Legislation Aimed at Curbing Fentanyl Deaths. JAMA Health Forum. 2023 Jan 06; 4(1):e225202. PMID: 36705915.

    Read at: PubMed
  • Published on 11/22/2022

    Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, Chandler R, Villani J, Walsh S, Talbert J. The prevalence of opioid use disorder in Kentucky's counties: A two-year multi-sample capture-recapture analysis. Drug Alcohol Depend. 2023 Jan 01; 242:109710. PMID: 36469995.

    Read at: PubMed
  • Published on 11/19/2022

    Doogan NJ, Mack A, Wang J, Crane D, Jackson R, Applegate M, Villani J, Chandler R, Barocas JA. Opioid Use Disorder Among Ohio's Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. Am J Epidemiol. 2022 Nov 19; 191(12):2098-2108. PMID: 36004683.

    Read at: PubMed
  • Published on 11/3/2022

    Lazarus JV, Romero D, Kopka CJ, Karim SA, Abu-Raddad LJ, Almeida G, Baptista-Leite R, Barocas JA, Barreto ML, Bar-Yam Y, Bassat Q, Batista C, Bazilian M, Chiou ST, Del Rio C, Dore GJ, Gao GF, Gostin LO, Hellard M, Jimenez JL, Kang G, Lee N, Maticic M, McKee M, Nsanzimana S, Oliu-Barton M, Pradelski B, Pyzik O, Rabin K, Raina S, Rashid SF, Rathe M, Saenz R, Singh S, Trock-Hempler M, Villapol S, Yap P, Binagwaho A, Kamarulzaman A, El-Mohandes A. A multinational Delphi consensus to end the COVID-19 public health threat. Nature. 2022 Nov; 611(7935):332-345. PMID: 36329272.

    Read at: PubMed
  • Published on 10/17/2022

    Barocas JA, Strathdee SA. Beyond Sex: Human Monkeypox Virus is an Emerging Threat to Marginalized Populations. Open Forum Infect Dis. 2022 Nov; 9(11):ofac551. PMID: 36381615.

    Read at: PubMed
  • Published on 8/24/2022

    Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022 Aug 24; 75(1):e1112-e1119. PMID: 34499124.

    Read at: PubMed
  • Published on 6/26/2022

    Wheeler A, Valerio H, Cunningham EB, Martinello M, Barocas JA, Colledge-Frisby S, Treloar C, Amin J, Henderson C, Read P, Matthews GV, Dunlop AJ, Gorton C, Hayllar J, Alavi M, Murray C, Marks P, Silk D, Degenhardt L, Dore GJ, Grebely J. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. Drug Alcohol Depend. 2022 Aug 01; 237:109543. PMID: 35772249.

    Read at: PubMed

View 75 more publications: View full profile at BUMC

View all profiles